Overall rank by patents
#27,791
of 49,997 tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 8 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Vistagen ranks #27,791 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 8 technology areas.
USPTO PatentsView assignee plate
Corpus R27791 · US Corporation #27,791 · 10 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Vhit S.p.A. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Vistagen Therapuetics · this assignee
27 score
3D Lighting… · lowest
7 score
What this shows Vistagen's Innovation Score is 26.5/100 (20th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Vistagen Therapuetics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 60% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (3 grants) versus a trough of 1 in 2017. By volume, Vistagen sits between Vhit S.p.A. and Voxy, Inc.
Vistagen Therapuetics, Inc. shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Vhit S.p.A.
10 patents
Viking Tech Corporation
10 patents
Vishay Sprague, Inc.
10 patents
Vismunda SRL
10 patents
Vivere Ltd.
10 patents
Voestalpine VAE GMBH
10 patents
Voti Inc.
10 patents
Voxy, Inc
10 patents
Vistagen Therapuetics, Inc.
10 patents
What this shows Vistagen holds 10 patents at rank #27,748, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #27,748 in granted patent volume.
Other assignees with the most granted patents in Vistagen's primary technology class.
Vistagen's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
27 20th percentile higher than 20% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 10.0% |
| 2018 | 2 | 20.0% |
| 2019 | 1 | 10.0% |
| 2020 | 3 | 30.0% |
| 2021 | 1 | 10.0% |
| 2022 | 1 | 10.0% |
| 2024 | 1 | 10.0% |
Top 8 of 8 technology areas
Overall rank by patents
#27,791
of 49,997 tracked assignees
26.5 out of 100
What to do with this data
Vistagen Therapuetics, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.